Lilly Expects Alimta Advisory Committee Review For Non-Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
FDA is considering the pemetrexed sNDA for a July 27 Oncologic Drugs Advisory Committee meeting. First quarter sales of Alimta were $12 mil., including $7 mil. in initial stocking for the mesothelioma agent.
You may also be interested in...
Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.
Janet Woodcock has been in the lead in the commissioner race for months without an announcement, but now serious doubts are being cast on her candidacy, including the tone of remarks at a White House press briefing.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.